Please login or register to print this page.

Clinical Articles, Lead Article

New T-wave morphology analysis system

An analysis system which enables biopharmaceutical companies to analyse detailed morphology of the electrocardiography (ECG) T-wave (QT Guard Plus™, eResearchTechnology, Inc.) is to be introduced to the clinical trial industry, following an agreement between its manufacturers and GE Healthcare.

The system identifies and quantifies characteristic changes in the shape of the T-wave found in drugs that produce Torsades de Pointes (TdP). The ability to perform this quantitative analysis could help to distinguish between drugs which are proarrhythmic and those which are not.

Screen shot 2014-04-30 at 11.42.28

© Jer5150 (from

“We believe that T-wave morphology analysis may help to better assess the arrhythmogenic potential of drugs which have a small or equivocal QT effect, and may be a very useful adjunct to traditional QT studies,” said Dr Robert Kleiman, eResearchTechnology, Inc.’s Chief Medical Officer. “The initial peer-reviewed literature is very promising…T-wave morphology analysis may help improve cardiac safety while preserving the drug development pipeline.”

For more information, please visit

Published on: April 30, 2014

Members Area

Log in or Register now.

 For healthcare professionals only
Angina book sky



Subscribe to our RSS feed


Sign up for our regular email newsletters & be the first to know about fresh articles and site updates.


    None Found


  • ArrhythmiaAlliance
  • Stars
  • Anticoagulation Europe
  • Atrial Fibrillation Association

You are not logged in

You need to be a member to print this page.
Sign up for free membership, or log in.

You are not logged in

You need to be a member to download PDF's.
Sign up for free membership, or log in.